Ionis Pharmaceuticals IONS Increase (decrease) in other current liabilities
Increase (decrease) in other current liabilities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherCurrentLiabilities.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's increase (decrease) in other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's increase (decrease) in other current liabilities?
- Ionis Pharmaceuticals (IONS) reported increase (decrease) in other current liabilities of $21M in Q1 2026.
- How has Ionis Pharmaceuticals's increase (decrease) in other current liabilities changed year-over-year?
- Ionis Pharmaceuticals's increase (decrease) in other current liabilities increased by 6207.2% year-over-year, from $333K to $21M.
- What does increase (decrease) in other current liabilities mean?
- The net change in miscellaneous short-term debts and obligations.
- How do you interpret increase (decrease) in other current liabilities?
- An increase suggests rising short-term operational obligations, while a decrease indicates the settlement of these liabilities.
- How does increase (decrease) in other current liabilities compare across companies?
- Commonly found in the cash flow statement under changes in working capital for most public companies.